Panel Discussion: Business as Usual or Back to the Drawing Board? Rethinking IPF Trial Design in a Three Antifibrotic Era
- Has the Approval of New Antifibrotics Fundamentally Changed IPF Trial Design? Exploring whether the introduction of additional approved therapies requires a paradigm shift toward combination trials and active comparators, or whether traditional development approaches remain valid
- Managing Background Therapies in an Evolving Standard of Care Debating strategies for incorporating monotherapy, prior antifibrotic exposure, and real-world combination regimens without compromising interpretability or feasibility of clinical trials.
- Lessons from Other Crowded Therapeutic Areas Considering how fields such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis have continued drug development despite multiple approved therapies, and whether ILD should follow a similar path.
- Designing Future Trials as the Pipeline Expands Anticipating how additional approvals may influence eligibility criteria, stratification strategies, and expectations for head-to-head or combination studies.